CNDD’s original intellectual property (IP) and technologies have contributed to economic development in the state. See some of our start-ups!
Enfuego Therapeutics Inc. is focused on further developing RNAi-based cancer therapeutics.
Inhalon Biopharma Inc. seeks to advance “muco-trapping” monoclonal antibodies for use in treating and preventing respiratory infections. The lead product is an inhalable antibody for treatment of RSV infections, which infects over 2.5M children in the U.S. each year and is the leading cause of viral infection mediated hospitalization.
DelAQUA Pharmaceuticals, Inc., is a biopharmaceutical company whose proprietary technology enables it to create novel products based upon new chemical entities as well as enhance the performance of already-approved drugs that have major market shares. The Company’s platform technology uses non-PEG stealth approach that has been validated across dozens of very poorly soluble active pharmaceutical ingredients of different classes. The technology allows to greatly enhance the solubility and stability of drugs and drug candidates and to improve their efficacy and safety, thus widening their therapeutic window. delAQUA offers partnering and co-development of novel drug formulations with Pharmas including use of their proprietary compounds in delAQUA formats.
OncoTrap is based on the drug target-binding protein molecules developed by using in vitro protein selection and protein engineering. The company aims at applying these affinity molecules to trap the immunosuppressive signals in the microenvironment of diseased tissues for the immunotherapy of major solid tumors and autoimmune diseases.
Their AceIMMune platform enables intracellular targeting of molecules to immune cells without use of surface receptors/ligands and with increased potency and reduced off-target toxicities. The company has validated the technology preclinically in multiple in vivo models of cancer, autoimmune diseases and infectious diseases. It is compatible for use with most molecules and peptides and allows tunable drug release kinetics.
Ostrea Bio develops therapies for the treatment of lysosomal storage diseases.
AI Tracking Solutions is using artificial intelligence to enable automated analysis of video microscopy data common in the research setting.
Panacise Bio aims at developing the technology platforms for the next generation Pro-CAR-T-cells that are activated in tumor microenvironment and therefore can be used for the treatment of various solid tumors.
Falcon Therapeutics is developing an entirely new approach to Glioblastoma therapy that uses revolutionary stem cell technology to create personalized genetically engineered neural stem cell therapies from the skin of cancer patients.
Mucommune is a privately held company seeking to advance “muco-trapping” monoclonal antibodies for use in reinforcing female reproductive health. The technology is based on engineering the Fc region of IgG antibodies to interact with mucins which enables antibodies to immobilize viral and bacterial pathogens in different mucosal secretions. Mucommune’s lead product is a non-hormonal contraceptive vaginal ring that releases muco-trapping mAb that can block sperm from reaching the egg by trapping it in cervicovaginal mucus.
Capio Biosciences is focused on delivering high-value oncology diagnostics that can help inform patient care decisions and improve outcomes. Capio Biosciences is currently developing an advanced platform called CapioCyte™ for the capture of circulating tumor cells (CTCs) from whole blood. By utilizing a combination of biomimetic cell rolling and dendrimer-mediated multivalent cell capture, CapioCyte delivers significantly greater capture sensitivity than other platforms currently available.
NeuroNano Pharma has developed a series of formulation and delivery technologies that when used with current or newly discovered compounds it can 1) preserve biologics as they traverse the body, 2) improve the transport of polypeptides, proteins, hormones, enzymes and small molecules across cell membranes and tissue barriers, including the blood brain barrier, and 3) improve the release of drugs encapsulated in liposomes. NeuroNano technology has therapeutic applications in CNS disorders, metabolic diseases, cancer and ophthalmic disease.
William Zamboni and Stephen Eckel
ChemoGLO is focused on the identification and quantification of trace surface are chemotherapy contamination in hospital and pharmacy preparation and administration areas. The ChemoGLOTM Wipe Kit uses a simple procedure to accurately quantify trace amounts of the contaminants docetaxel, paclitaxel, 5-FU, cyclophosphamide, and ifosfamide that commonly occur in hospitals and pharmacies where these drugs are processed and administered.
Arcato Laboratories’ mission is to become a leading oral health company by commercializing unique, proprietary products to serve specialty oral healthcare practitioners, such as orthodontists and oral surgeons. Arcato’s first product, a medical device named OraWaxTM, targets orthodontists and their patients as the first effective treatment for oral discomfort caused by orthodontic appliances (braces). Arcato is also developing future products by expanding on its current proprietary technology platform, as well as aggressively seeking to create or in-license complementary intellectual property.
Russell Mumper and Michael Jay
Capture Pharmaceuticals, Inc. is developing a radionuclide decorporation agent that works by binding radioactive elements in the bloodstream and enhancing their elimination before they can be trapped inside the liver and bones where they can do much damage. Because the agent can be taken orally, it has significant advantages over currently available products, which must be administered by intravenous injection, for use in a mass casualty scenario, and is superior to other competing technologies. Capture is also pursuing the use of their product in other metal-overload conditions and diseases.
Qualiber, Inc. is commercializing the novel nanoparticle-based drug delivery technologies developed in Professor Leaf Huang’s lab. The novel nanoparticles address unmet needs in the delivery of small molecules, siRNA, and peptides across multiple therapeutic areas. Using this delivery platform, the company plans to create a sustainable product pipeline for small-molecule drugs that could be improved and made safer via novel delivery formulations.